AORT Artivion, Inc. Common Stock
NYSE · Health Care · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 7, 2026
$22.31
· of 52w range
· above low
· to high
$19.1652w low
$48.2552w high
Market Cap (MRQ)
$1.12B
P/E (TTM)
-371.8
EPS (TTM)
$-0.06
Revenue (TTM)
$471M
your badges
52W Range
$19–$48
Analyst Rating
BUY
Price Target
$42
P/E
-371.8
ROE
-0.73%
Net Profit Margin
-0.67%
Your badge strip is empty — pin a metric anywhere on this page.
AORT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$22.31
Market Cap (MRQ)
$1.12B
P/E (TTM)
-371.8
EPS (TTM)
$-0.06
Revenue (TTM)
$471M
ROE (TTM)
-0.73%
Debt/Equity (MRQ)
0.8
52W Range
$19–$48
AORT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Dec. 28, 2000 | 3-for-2 | Forward |
| July 1, 1996 | 2-for-1 | Forward |
About Artivion, Inc. Common Stock Company overview from Wikipedia
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.
## History
Artivion was founded as CryoLife in Sarasota, Florida in 1984 by Steven Anderson and Robert McNally. Anderson acted as the company’s president and CEO from its founding. The company later moved from Sarasota to the Atlanta metropolitan area. In January 2022 the company changed its name to Artivion, Inc.
In 2000, CryoLife began offering a surgical adhesive called BioGlue used for sealing surgical lacerations under high pressure, such as in arteries.
In February 2008, the FDA gave CryoLife approval for a new kind of heart valve, made from human tissues, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue. In giving the approval, the FDA said the new valve, called the CryoValve SynerGraft Pulmonary Valve, had less of a chance of rejection than previous valves.
In 2010, CryoLife acquired the rights to manufacture and distribute PerClot, an absorbable hemostatic powder used in surgery.
In January 2016, the company acquired On-X Life Technologies and its principal product, a mechanical heart valve called the On-X aortic valve replacement, for $130 million.
In October 2017, Artivion acquired JOTEC GmbH, a German-based developer of medical devices for aortic and peripheral vascular diseases, for €225 million. In September 2020, the company acquired Ascyrus Medical.
In 2021, the company received FDA premarket application approval of its PerClot absorbable hemostatic system, which comprised PerClot granules and a delivery system for surgical use. Baxter International agreed to buy PerClot from Artivion in 2021. In 2023, after final FDA approval of the product, the purchase was completed.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealth Care
industryHealth Care
employees1,800
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$441M2016-12-31 → 2025-12-31
EPS$0.212016-12-31 → 2025-12-31
Free Cash Flow$839.0K2016-12-31 → 2025-12-31
Net margin-0.67%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | AORT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -371.85Y avg ≈5.0 | ≈5.0 | · | · | |
| P/S (TTM) | 2.45Y avg ≈3.0 | ≈3.0 | 3.9 | Undervalued | |
| P/B (MRQ) | 2.55Y avg ≈3.4 | ≈3.4 | 3.9 | Undervalued | |
| EV / EBITDA | 22.55Y avg ≈32.6 | ≈32.6 | · | · | |
| Price / FCF (TTM) | -122.35Y avg ≈554.3 | ≈554.3 | · | · | |
| Price / Cash Flow (TTM) | 26.85Y avg ≈-54.3 | ≈-54.3 | 38.0 | Overvalued | |
| EV / Revenue | 2.95Y avg ≈3.7 | ≈3.7 | · | · | |
| EV / FCF | 1508.15Y avg ≈592.1 | ≈592.1 | · | · | |
| Price / Tangible Book (MRQ) | 3.8 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | AORT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin (TTM) | 64.4%5Y avg ≈64.8% | ≈64.8% | 64.0% | In line | |
| Operating Margin (TTM) | 4.4%5Y avg ≈4.8% | ≈4.8% | -7.6% | In line | |
| EBITDA Margin (TTM) | 9.6%5Y avg ≈11.4% | ≈11.4% | -7.6% | In line | |
| Pretax Margin (TTM) | 0.47%5Y avg ≈-2.9% | ≈-2.9% | -8.7% | In line | |
| Net Profit Margin (TTM) | -0.67%5Y avg ≈-4.2% | ≈-4.2% | -9.5% | In line | |
| ROA (TTM) | -0.33%5Y avg ≈-1.8% | ≈-1.8% | -20.2% | Top tier | |
| ROE (TTM) | -0.73%5Y avg ≈-5.1% | ≈-5.1% | -25.1% | Top tier | |
| ROIC | 3.4%5Y avg ≈3.8% | ≈3.8% | -31.3% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | AORT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.85Y avg ≈1.0 | ≈1.0 | 0.6 | High debt | |
| Current Ratio (MRQ) | 3.55Y avg ≈4.6 | ≈4.6 | 5.6 | Low liquidity | |
| Quick Ratio | 1.55Y avg ≈2.0 | ≈2.0 | 3.6 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.85Y avg ≈1.0 | ≈1.0 | 0.6 | High debt |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | AORT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 13.6%5Y avg ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y | 12.0%5Y avg ≈11.0% | ≈11.0% | · | · | |
| Revenue CAGR 5Y | 11.8% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | AORT | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.55Y avg ≈0.5 | ≈0.5 | 0.5 | In line | |
| Inventory Turnover | 1.85Y avg ≈1.6 | ≈1.6 | 1.8 | In line | |
| Receivables Turnover | 5.25Y avg ≈5.4 | ≈5.4 | 6.9 | Weak | |
| Revenue / Employee | ≈$245.2K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Annualized Payout≈$0.12
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Dec 9, 2015 | $0.03 | USD | ≈1.2% |
| Sep 9, 2015 | $0.03 | USD | ≈1.2% |
| Jun 10, 2015 | $0.03 | USD | ≈1.1% |
| Mar 11, 2015 | $0.03 | USD | ≈1.2% |
| Dec 10, 2014 | $0.03 | USD | ≈1.1% |
| Sep 10, 2014 | $0.03 | USD | ≈1.2% |
| Jun 11, 2014 | $0.03 | USD | ≈1.3% |
| Mar 12, 2014 | $0.03 | USD | ≈1.2% |
| Dec 11, 2013 | $0.03 | USD | ≈1.1% |
| Sep 11, 2013 | $0.03 | USD | ≈1.7% |
| Jun 12, 2013 | $0.03 | USD | ≈1.7% |
| Mar 12, 2013 | $0.03 | USD | ≈1.2% |
| Dec 12, 2012 | $0.03 | USD | ≈0.83% |
| Sep 12, 2012 | $0.03 | USD | ≈0.45% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-518.1%
Next Report
Nov 04, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 5, 2026 | $-0.28 | $0.01 | -2845.1% |
| March 31, 2026 | $0.03 | $0.05 | -40.1% | |
| Dec. 31, 2025 | $0.05 | $0.08 | -40.0% | |
| Sept. 30, 2025 | $0.06 | $0.02 | 242.9% | |
| June 30, 2025 | $0.08 | $-0.00 | — | |
| March 31, 2025 | $-0.01 | $-0.12 | 91.7% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Cost of Revenue | $157M | $140M | $125M | $111M | $101M | $85M | $93M | $90M | $61M | $61M | $55M | $53M | |
| Gross Profit | $284M | $249M | $229M | $203M | $198M | $168M | $183M | $173M | $129M | $119M | $91M | $91M | |
| R&D Expense | $31M | $28M | $29M | $39M | $36M | $24M | $23M | $23M | $19M | $13M | $10M | $9M | |
| SG&A Expense | $226M | $181M | $209M | $157M | $170M | $141M | $143M | $141M | $101M | $92M | $75M | $74M | |
| Operating Expenses | $257M | $210M | $238M | $196M | $205M | $165M | $166M | $164M | $121M | $105M | $85M | $82M | |
| Operating Income | $34M | $39M | $6M | $6M | $8M | $2M | $17M | $9M | $8M | $22M | $5M | $9M | |
| Interest Expense | · | · | $25M | $18M | $17M | $17M | $15M | $16M | $5M | $3M | $62.0K | $175.0K | |
| Interest Income | $763.0K | $1M | $1M | $147.0K | $79.0K | $217.0K | $738.0K | $226.0K | $212.0K | $72.0K | $45.0K | $50.0K | |
| Other Non-op | $10M | $-10M | $-3M | $-3M | $-6M | $-3M | $-1M | $-141.0K | $260.0K | $-437.0K | $-484.0K | $-540.0K | |
| Pretax Income | $15M | $-8M | $-22M | $-15M | $-15M | $-17M | $2M | $-6M | $4M | $18M | $6M | $9M | |
| Income Tax | $5M | $6M | $9M | $4M | $7.0K | $-492.0K | $-76.0K | $-4M | $-143.0K | $8M | $2M | $1M | |
| Net Income | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| EPS (Basic) | $0.22 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.33 | $0.14 | $0.26 | |
| EPS (Diluted) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 | |
| Shares (Basic) | 45,335,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,118,000 | 36,412,000 | 33,008,000 | 31,855,000 | 27,744,000 | 27,379,000 | |
| Shares (Diluted) | 47,162,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,860,000 | 36,412,000 | 34,163,000 | 32,822,000 | 28,542,000 | 28,313,000 | |
| EBITDA | $56M | $63M | $29M | $29M | $32M | $23M | $35M | $27M | $18M | $30M | · | $15M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65M | $53M | $59M | $39M | $55M | $61M | $34M | $41M | $40M | $57M | $38M | $33M | |
| Receivables | $90M | $79M | $72M | $62M | $53M | $46M | $53M | $47M | $48M | $28M | $23M | $21M | |
| Inventory | $92M | $80M | $82M | $74M | $77M | $73M | $53M | $45M | $47M | $26M | $15M | $13M | |
| Prepaid Expense | $43M | $19M | $16M | $18M | $15M | $14M | $12M | $7M | $5M | $3M | $5M | $5M | |
| Current Assets | $358M | $290M | $281M | $247M | $248M | $235M | $187M | $179M | $179M | $147M | $110M | $106M | |
| PP&E (Net) | $65M | $36M | $38M | $39M | $38M | $33M | $32M | $31M | $34M | $19M | $11M | $12M | |
| PP&E (Gross) | · | · | · | $127M | $120M | $111M | $103M | $96M | $93M | $74M | $64M | $62M | |
| Accum. Depreciation | · | · | · | $88M | $82M | $78M | $71M | $65M | $60M | $55M | $53M | $50M | |
| Goodwill | $254M | $241M | $247M | $244M | $250M | $260M | $187M | $189M | $188M | $78M | $11M | $11M | |
| Intangibles | $124M | $128M | $143M | $151M | $167M | $186M | $115M | $118M | $130M | $1M | $1M | $2M | |
| Other Non-current Assets | $15M | $24M | $9M | $7M | $8M | $15M | $14M | $8M | $7M | $2M | $6M | $5M | |
| Total Assets | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Accounts Payable | $16M | $18M | $13M | $12M | $10M | $10M | $10M | $8M | $10M | $6M | $5M | $4M | |
| Accrued Liabilities | $16M | $12M | $10M | $12M | $8M | $7M | $7M | $7M | $12M | $5M | $3M | $3M | |
| Current Liabilities | $102M | $67M | $58M | $50M | $45M | $60M | $45M | $35M | $43M | $30M | $20M | $21M | |
| Capital Leases | $34M | $40M | $44M | $41M | $45M | $14M | $18M | $0 | $7M | $11.0K | · | · | |
| Deferred Tax | $24M | $20M | $22M | $24M | $29M | $35M | $26M | $27M | $30M | $7.0K | · | · | |
| Other Non-current Liabilities | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $7M | $8M | $5M | $3M | $3M | |
| Total Liabilities | $437M | $513M | $511M | $478M | $492M | $461M | $320M | $296M | $313M | $107M | $26M | $27M | |
| Long-term Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Total Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Common Stock | $493.0K | $434.0K | $426.0K | $418.0K | $414.0K | $404.0K | $390.0K | $385.0K | $376.0K | $342.0K | $298.0K | $292.0K | |
| Retained Earnings | $-51M | $-61M | $-48M | $-17M | $2M | $20M | $37M | $35M | $38M | $34M | $23M | $23M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $13M | $12M | $11M | $9M | |
| AOCI | $-3M | $-25M | $-12M | $-22M | $-10M | $7M | $-9M | $-6M | $2M | $-429.0K | $-76.0K | $-121.0K | |
| Stockholders' Equity | $448M | $276M | $282M | $284M | $301M | $329M | $286M | $275M | $277M | $209M | $155M | $149M | |
| Liabilities + Equity | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Shares Outstanding | 49,330,000 | 43,432,000 | 42,569,000 | 41,830,000 | 41,397,000 | 40,394,000 | 39,018,000 | 38,463,000 | 37,618,000 | 34,230,000 | 29,766,000 | 29,229,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $22M | $24M | $23M | $22M | $24M | $21M | $18M | $18M | $10M | $8M | $6M | $6M | |
| Stock-based Comp | $24M | $14M | $14M | $12M | $11M | $7M | $9M | $6M | $7M | $6M | $5M | $3M | |
| Deferred Tax | $37.0K | $-2M | $-1M | $-885.0K | $-6M | $816.0K | $-2M | $-6M | $-1M | $3M | $1M | $173.0K | |
| Amort. of Intangibles | $14M | $16M | $15M | $15M | $17M | $14M | $11M | $11M | $5M | $4M | $2M | $2M | |
| Other Non-cash | $-17M | $-1M | $13M | $-20M | $-17M | $611.0K | $-11M | $-5M | $-8M | $-8M | · | $-9M | |
| Operating Cash Flow | $40M | $22M | $19M | $-5M | $-3M | $12M | $16M | $10M | $11M | $20M | $11M | $8M | |
| CapEx | $39M | $11M | $10M | $11M | $13M | $7M | $8M | $6M | $7M | $6M | $3M | $4M | |
| Investing Cash Flow | $-42M | $-28M | $-502.0K | $-11M | $6M | $-73M | $-24M | $-7M | $-171M | $-79M | $-4M | · | |
| Debt Issued | $0 | $184M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $-210.0K | $-28M | $-3M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | $2M | $3M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $6M | |
| Net Stock Activity | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | · | $-3M | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | $3M | $3M | |
| Financing Cash Flow | $11M | $2M | $865.0K | $-2M | $-12M | $94M | $-1M | $-3M | $143M | $73M | $-3M | · | |
| Net Change in Cash | $11M | $-5M | $20M | $-16M | $-7M | $28M | $-8M | $1M | $-17M | $14M | $4M | $-4M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | $145.0K | $3M | |
| Free Cash Flow | $839.0K | $11M | $11M | $-14M | $-16M | $5M | $8M | $4M | $4M | $14M | · | $4M | |
| Levered FCF | · | · | $-25M | $-38M | $-33M | $-11M | $-8M | $-3M | $-925.8K | $12M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% | 66.3% | 66.3% | 65.8% | 67.8% | 65.9% | · | 63.1% | |
| Operating Margin | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% | 0.96% | 6.2% | 3.5% | 4.2% | 12.1% | · | 6.1% | |
| Net Margin | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | -6.6% | 0.62% | -1.1% | 1.9% | 6.0% | · | 5.1% | |
| Pretax Margin | 3.4% | -1.9% | -6.1% | -4.8% | -5.0% | -6.8% | 0.60% | -2.4% | 1.9% | 10.2% | · | 6.0% | |
| EBITDA Margin | 12.7% | 16.2% | 8.1% | 9.1% | 10.7% | 9.1% | 12.8% | 10.4% | 9.3% | 16.7% | · | 10.3% | |
| ROA | 1.2% | -1.7% | -4.0% | -2.5% | -1.9% | -2.4% | 0.29% | -0.49% | 0.82% | 4.3% | · | 4.2% | |
| ROE | 2.2% | -4.6% | -11.1% | -7.1% | -4.9% | -5.1% | 0.61% | -1.0% | 1.5% | 5.9% | · | 5.0% | |
| ROIC | 3.4% | 11.7% | 1.4% | 1.3% | 1.3% | 0.38% | 3.6% | 0.84% | 1.7% | 4.5% | · | 5.0% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 | 3.9 | 4.1 | 5.2 | 4.2 | 4.9 | · | 5.1 | |
| Quick Ratio | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 | 1.8 | 1.9 | 2.6 | 2.0 | 2.8 | · | 2.6 | |
| Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| LT Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| Interest Coverage | · | · | 0.2 | 0.3 | 0.5 | 0.1 | 1.1 | 0.6 | 1.6 | 7.3 | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.4 | 0.7 | · | 0.8 | |
| Inventory Turnover | 1.8 | 1.7 | 1.6 | 1.5 | 1.4 | 1.4 | 1.9 | 1.9 | 1.7 | 3.0 | · | 4.7 | |
| Receivables Turnover | 5.2 | 5.1 | 5.3 | 5.5 | 6.0 | 5.1 | 5.5 | 5.6 | 5.0 | 7.0 | · | 7.4 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $9.09 | $6.36 | $6.62 | $6.80 | $7.26 | $8.14 | $7.32 | $7.15 | $7.37 | $6.11 | · | $5.09 | |
| Revenue / Share | $9.36 | $9.32 | $8.69 | $7.84 | $7.67 | $6.69 | $7.30 | $7.22 | $5.55 | $5.50 | · | $5.11 | |
| Cash Flow / Share | $0.85 | $0.53 | $0.46 | $-0.13 | $-0.07 | $0.33 | $0.42 | $0.27 | $0.32 | $0.60 | · | $0.29 | |
| Cash / Share | $1.32 | $1.23 | $1.38 | $0.94 | $1.33 | $1.52 | $0.87 | $1.08 | $1.06 | $1.65 | · | $1.14 | |
| Dividend / Share | · | · | · | · | · | · | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.12 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | · | · | · | $0.12 | $0.12 | |
| EPS (TTM) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 13.6% | 9.8% | 12.8% | 5.0% | 18.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.0% | 9.1% | 11.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.8% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Net Income TTM | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| Market Cap | $2.25B | $1.24B | $761M | $507M | $842M | $954M | $1.06B | $1.09B | $720M | $656M | · | $331M | |
| Enterprise Value | $2.40B | $1.50B | $1.01B | $776M | $1.10B | $1.18B | $1.24B | $1.27B | $899M | $670M | · | · | |
| P/E | 217.2 | -89.3 | -23.8 | -25.2 | -53.6 | -53.7 | 541.8 | -354.8 | 174.1 | 59.8 | 77.0 | 45.3 | |
| P/S | 5.1 | 3.2 | 2.2 | 1.6 | 2.8 | 3.8 | 3.8 | 4.2 | 3.8 | 3.6 | · | 2.3 | |
| P/B | 5.0 | 4.5 | 2.7 | 1.8 | 2.8 | 2.9 | 3.7 | 4.0 | 2.6 | 3.1 | · | 2.2 | |
| P / Tangible Book | 31.9 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 56.4 | 55.8 | 40.4 | -98.4 | -325.9 | 77.1 | 66.8 | 110.5 | 66.7 | 33.2 | · | 40.8 | |
| P / FCF | 2681.7 | 112.4 | 66.8 | -35.8 | -53.7 | 189.2 | 136.3 | 266.6 | 172.7 | 48.5 | · | 87.0 | |
| EV / EBITDA | 42.7 | 23.8 | 35.0 | 27.1 | 34.2 | 51.1 | 35.0 | 46.2 | 50.8 | 22.2 | · | · | |
| EV / FCF | 2860.7 | 136.0 | 88.6 | -54.7 | -70.0 | 234.9 | 159.8 | 309.4 | 215.6 | 49.6 | · | · | |
| EV / Revenue | 5.4 | 3.9 | 2.9 | 2.5 | 3.7 | 4.7 | 4.5 | 4.8 | 4.7 | 3.7 | · | · | |
| Dividend Yield | · | · | · | · | · | · | · | · | · | · | · | 0.99% | |
| Earnings Yield | 0.46% | -1.1% | -4.2% | -4.0% | -1.9% | -1.9% | 0.18% | -0.28% | 0.57% | 1.7% | 1.3% | 2.2% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | · | 45.0% | |
| Annual Payout | · | · | · | · | · | · | · | · | · | · | $3M | $3M |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $126M | $116M | $116M | $113M | $113M | $99M | $97M | $96M | $98M | $97M | $94M | $88M | $89M | $83M | $79M | $77M | |
| Cost of Revenue | $45M | $41M | $43M | $39M | $40M | $35M | $36M | $35M | $35M | $34M | $33M | $32M | $31M | $30M | $29M | $28M | |
| Gross Profit | $81M | $75M | $73M | $74M | $73M | $64M | $62M | $61M | $63M | $63M | $61M | $56M | $58M | $54M | $51M | $49M | |
| R&D Expense | $9M | $9M | $9M | $8M | $7M | $7M | $7M | $7M | $7M | $7M | $8M | $6M | $7M | $7M | $8M | $12M | |
| SG&A Expense | $80M | $61M | $57M | $57M | $58M | $55M | $51M | $50M | $49M | $31M | $50M | $51M | $57M | $50M | $38M | $41M | |
| Operating Expenses | $89M | $70M | $66M | $65M | $65M | $61M | $59M | $57M | $57M | $38M | $58M | $58M | $65M | $58M | $47M | $53M | |
| Operating Income | $-8M | $6M | $11M | $13M | $8M | $2M | $3M | $4M | $7M | $25M | $3M | $-1M | $8M | $-4M | $4M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $8M | · | $7M | $6M | $6M | · | $5M | |
| Interest Income | $367.0K | $205.0K | $311.0K | $240.0K | $68.0K | $144.0K | $374.0K | $366.0K | $353.0K | $374.0K | $398.0K | $339.0K | $265.0K | $75.0K | $61.0K | $40.0K | |
| Other Non-op | $4M | $-286.0K | $1M | $399.0K | $5M | $3M | $-10M | $2M | $-983.0K | $-1M | $2M | $-2M | $-4M | $963.0K | $4M | $-4M | |
| Pretax Income | $-12M | $339.0K | $7M | $7M | $3M | $-2M | $-17M | $-1M | $-2M | $13M | $-591.0K | $-9M | $-3M | $-9M | $3M | $-13M | |
| Income Tax | $2M | $-1M | $4M | $554.0K | $2M | $-2M | $-119.0K | $1M | $-306.0K | $5M | $3M | $382.0K | $725.0K | $5M | $1M | $1M | |
| Net Income | $-14M | $1M | $2M | $7M | $1M | $-505.0K | $-16M | $-2M | $-2M | $8M | $-4M | $-10M | $-3M | $-14M | $2M | $-14M | |
| EPS (Basic) | $-0.28 | $0.03 | $0.06 | $0.14 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| EPS (Diluted) | $-0.28 | $0.03 | $0.06 | $0.13 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| Shares (Basic) | 48,541,000 | 48,074,000 | · | 47,233,000 | 44,296,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 41,290,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| Shares (Diluted) | 48,541,000 | 49,731,000 | · | 48,775,000 | 45,378,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 47,886,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| EBITDA | $-8M | $12M | · | $13M | $8M | $8M | · | $4M | $7M | $31M | · | $-1M | $8M | $2M | · | $-4M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77M | $56M | $65M | $73M | $53M | $38M | $53M | $56M | $55M | $51M | · | $53M | $49M | $31M | · | $38M | |
| Receivables | $98M | $92M | $90M | $88M | $91M | $88M | $79M | $76M | $74M | $74M | · | $64M | $65M | $63M | · | $57M | |
| Inventory | $103M | $98M | $92M | $91M | $87M | $82M | $80M | $84M | $81M | $82M | · | $79M | $78M | $76M | · | $73M | |
| Prepaid Expense | $27M | $45M | $43M | $22M | $25M | $20M | $19M | $19M | $20M | $17M | · | $17M | $19M | $20M | · | $17M | |
| Current Assets | $371M | $358M | $358M | $337M | $319M | $287M | $290M | $288M | $285M | $277M | · | $267M | $264M | $241M | · | $238M | |
| PP&E (Net) | $74M | $68M | $65M | $41M | $40M | $38M | $36M | $38M | $37M | $38M | · | $37M | $38M | $39M | · | $36M | |
| Goodwill | $350M | $252M | $254M | $254M | $254M | $245M | $241M | $249M | $244M | $245M | $247M | $243M | $246M | $246M | $244M | $235M | |
| Intangibles | $149M | $120M | $124M | $126M | $129M | $128M | $128M | $135M | $135M | $138M | · | $143M | $147M | $150M | · | $148M | |
| Other Non-current Assets | $15M | $16M | $15M | $29M | $27M | $25M | $24M | $21M | $14M | $13M | · | $8M | $8M | $8M | · | $7M | |
| Total Assets | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Accounts Payable | $21M | $18M | $16M | $16M | $19M | $12M | $18M | $11M | $12M | $10M | · | $11M | $10M | $9M | · | $11M | |
| Accrued Liabilities | $16M | $17M | $16M | $12M | $11M | $12M | $12M | $16M | $16M | $16M | · | $10M | $10M | $10M | · | $10M | |
| Current Liabilities | $107M | $93M | $102M | $86M | $67M | $52M | $67M | $153M | $51M | $46M | · | $55M | $56M | $44M | · | $46M | |
| Capital Leases | $36M | $34M | $34M | $38M | $39M | $39M | $40M | $41M | $42M | $43M | · | $43M | $40M | $41M | · | $41M | |
| Deferred Tax | $26M | $28M | $24M | $22M | $23M | $22M | $20M | $19M | $22M | $22M | · | $20M | $19M | $24M | · | $34M | |
| Other Non-current Liabilities | $9M | $9M | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $8M | · | $8M | $7M | $7M | · | $7M | |
| Total Liabilities | $626M | $433M | $437M | $419M | $418M | $497M | $513M | $498M | $494M | $489M | · | $503M | $495M | $477M | · | $488M | |
| Long-term Debt | $363M | $215M | $215M | $215M | $216M | $315M | $314M | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Total Debt | $363M | $215M | · | $215M | $216M | $315M | · | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Common Stock | $502.0K | $500.0K | $493.0K | $488.0K | $486.0K | $442.0K | $434.0K | $434.0K | $433.0K | $432.0K | · | $425.0K | $424.0K | $424.0K | · | $418.0K | |
| Retained Earnings | $-64M | $-50M | $-51M | $-54M | $-60M | $-62M | $-61M | $-45M | $-42M | $-40M | · | $-44M | $-34M | $-31M | · | $-19M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | · | $15M | $15M | $15M | · | $15M | |
| AOCI | $-12M | $-12M | $-3M | $-2M | $-3M | $-19M | $-25M | $-10M | $-16M | $-14M | · | $-21M | $-16M | $-18M | · | $-45M | |
| Stockholders' Equity | $446M | $450M | $448M | $439M | $420M | $294M | $276M | $305M | $295M | $295M | $282M | $272M | $283M | $280M | $284M | $255M | |
| Liabilities + Equity | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Shares Outstanding | 50,179,000 | 49,983,000 | 49,330,000 | 48,862,000 | 48,592,000 | 44,190,000 | 43,432,000 | 43,392,000 | · | · | 42,569,000 | 42,537,000 | 42,443,000 | 42,366,000 | 41,830,000 | 41,816,000 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | |
| Stock-based Comp | $8M | $8M | $4M | $6M | $6M | $8M | $3M | $4M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $3M | · | · | · | $6M | · | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | |
| Other Non-cash | · | $-15M | · | · | · | $-30M | · | · | · | $-22M | · | · | · | $-2M | · | · | |
| Operating Cash Flow | $-1M | $1M | $20M | $22M | $15M | $-17M | $10M | $11M | $6M | $-5M | $11M | $7M | $7M | $-6M | $-217.0K | $4M | |
| CapEx | $11M | $8M | $28M | $5M | $3M | $4M | $1M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Investing Cash Flow | $-129M | $-11M | $-31M | $-5M | $-3M | $-4M | $-11M | $-11M | $-3M | $-4M | $-3M | $-2M | $7M | $-3M | $-3M | $-3M | |
| Debt Issued | · | · | $0 | $0 | $0 | $0 | $-6M | $160M | $160M | $190M | $0 | $0 | $0 | $0 | · | · | |
| Net Debt Issued | · | $0 | · | · | · | $-66.0K | · | · | · | $-182M | · | · | · | · | · | · | |
| Stock Issued | $1M | $1M | $3M | $5M | $278.0K | $4M | $443.0K | $2M | $59.0K | $4M | $488.0K | $886.0K | $0 | $3M | $24.0K | $1M | |
| Net Stock Activity | · | $1M | · | · | · | $4M | · | · | · | $4M | · | · | · | $3M | · | · | |
| Financing Cash Flow | $152M | $463.0K | $2M | $2M | $3M | $4M | $174.0K | $1M | $-181.0K | $737.0K | $-2M | $-909.0K | $2M | $1M | $-859.0K | $252.0K | |
| Net Change in Cash | $22M | $-9M | $-9M | $20M | $16M | $-16M | $-3M | $1M | $4M | $-8M | $5M | $5M | $18M | $-9M | $2M | $-3M | |
| Free Cash Flow | · | $-7M | · | · | · | $-21M | · | · | · | $-9M | · | · | · | $-8M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-14M | · | · | · | $-18M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.0% | 64.8% | · | 65.6% | 64.7% | 64.2% | · | 63.7% | 64.6% | 64.6% | · | 64.0% | 65.1% | 64.5% | · | 63.4% | |
| Operating Margin | -6.7% | 5.0% | · | 11.1% | 7.4% | 2.2% | · | 4.6% | 6.6% | 26.0% | · | -1.4% | 8.6% | -4.6% | · | -5.3% | |
| Net Margin | -10.7% | 1.2% | · | 5.7% | 1.2% | -0.51% | · | -2.4% | -2.2% | 7.7% | · | -11.2% | -3.8% | -16.3% | · | -17.8% | |
| Pretax Margin | -9.3% | 0.29% | · | 6.2% | 3.1% | -2.3% | · | -1.3% | -2.5% | 13.1% | · | -10.7% | -3.0% | -10.7% | · | -16.3% | |
| EBITDA Margin | -6.7% | 10.4% | · | 11.1% | 7.4% | 7.7% | · | 4.6% | 6.6% | 32.0% | · | -1.4% | 8.6% | 2.2% | · | -5.3% | |
| ROA | -1.4% | 0.17% | · | 0.78% | 0.17% | -0.06% | · | -0.29% | -0.27% | 0.98% | · | -1.3% | -0.44% | -1.8% | · | -1.8% | |
| ROE | -3.1% | 0.38% | · | 1.8% | 0.38% | -0.17% | · | -0.79% | -0.73% | 2.6% | · | -3.7% | -1.2% | -4.7% | · | -4.8% | |
| ROIC | -1.2% | 3.6% | · | 1.8% | 0.51% | 0.08% | · | 1.3% | 0.93% | 2.5% | · | -0.22% | 1.7% | -1.0% | · | -0.80% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.9 | · | 3.9 | 4.8 | 5.5 | · | 1.9 | 5.6 | 6.0 | · | 4.9 | 4.7 | 5.5 | · | 5.2 | |
| Quick Ratio | 1.6 | 1.6 | · | 1.9 | 2.2 | 2.4 | · | 0.9 | 2.5 | 2.7 | · | 2.1 | 2.0 | 2.1 | · | 2.1 | |
| Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| LT Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 0.7 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.2 | · | -0.2 | 1.2 | -0.6 | · | -0.9 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.4 | · | 1.4 | 1.5 | 1.4 | · | 1.4 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.88 | $9.01 | · | $8.98 | $8.64 | $6.66 | · | $7.02 | · | · | · | $6.39 | $6.66 | $6.61 | · | $6.10 | |
| Revenue / Share | $2.59 | $2.34 | · | $2.32 | $2.49 | $2.34 | · | $2.29 | $2.35 | $2.03 | · | $2.15 | $2.19 | $2.06 | · | $1.92 | |
| Cash Flow / Share | · | $0.02 | · | · | · | $-0.40 | · | · | · | $-0.11 | · | · | · | $-0.15 | · | · | |
| Cash / Share | $1.54 | $1.12 | · | $1.50 | $1.10 | $0.85 | · | $1.29 | · | · | · | $1.26 | $1.15 | $0.73 | · | $0.90 | |
| EPS (TTM) | $-0.06 | $0.25 | · | $-0.25 | $-0.43 | $-0.51 | · | $-0.02 | $-0.21 | $-0.24 | · | $-0.60 | $-0.70 | $-0.73 | · | $-1.03 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $471M | $459M | · | $423M | $405M | $390M | · | $385M | $377M | $368M | · | $340M | $329M | $320M | · | $314M | |
| Net Income TTM | $-3M | $12M | · | $-9M | $-18M | $-21M | · | $-851.0K | $-8M | $-10M | · | $-25M | $-28M | $-29M | · | $-41M | |
| Market Cap | $1.13B | $1.83B | · | $2.07B | $1.51B | $1.09B | · | $1.16B | · | · | · | $645M | $730M | $555M | · | $579M | |
| Enterprise Value | $1.41B | $1.99B | · | $2.21B | $1.67B | $1.36B | · | $1.41B | · | · | · | $899M | $988M | $832M | · | $849M | |
| P/E | -374.5 | 146.5 | · | -169.4 | -72.3 | -48.2 | · | -1331.0 | -122.1 | -88.2 | · | -25.3 | -24.6 | -17.9 | · | -13.4 | |
| P/S | 2.4 | 4.0 | · | 4.9 | 3.7 | 2.8 | · | 3.0 | · | · | · | 1.9 | 2.2 | 1.7 | · | 1.8 | |
| P/B | 2.5 | 4.1 | · | 4.7 | 3.6 | 3.7 | · | 3.8 | · | · | · | 2.4 | 2.6 | 2.0 | · | 2.3 | |
| P / Tangible Book | · | 23.2 | · | 35.5 | 41.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 1586.1 | · | · | · | -64.1 | · | · | · | · | · | · | · | -90.2 | · | · | |
| EV / Revenue | 3.0 | 4.3 | · | 5.2 | 4.1 | 3.5 | · | 3.7 | · | · | · | 2.6 | 3.0 | 2.6 | · | 2.7 | |
| Dividend Yield | 0.30% | 0.19% | · | 0.16% | 0.23% | 0.31% | · | 0.30% | · | · | · | 0.53% | 0.47% | 0.61% | · | 0.59% | |
| Earnings Yield | -0.27% | 0.68% | · | -0.59% | -1.4% | -2.1% | · | -0.08% | -0.82% | -1.1% | · | -4.0% | -4.1% | -5.6% | · | -7.4% | |
| Annual Payout | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $441M | $389M | $354M | $314M | $299M |
| Gross Margin % | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% |
| Operating Margin % | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% |
| Net Income | $10M | $-13M | $-31M | $-19M | $-15M |
| Diluted EPS | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 |
| Current Ratio | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 |
| Quick Ratio | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $839.0K | $11M | $11M | $-14M | $-16M |
Institutional owners (13F) 212 filers · $1.2B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
212
Value held
$1.2B
New positions
34
Exited positions
65
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 34 (-7 vs prior Q) | 65 (+29 vs prior Q) | 81 (-12 vs prior Q) | 56 (-7 vs prior Q) | +2.0M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $149,965,153 | 6,674,017 | 12.78% | Shares |
| VANGUARD GROUP INC | $144,587,760 | 3,170,089 | 12.33% | Shares |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $71,566,000 | 3,184,974 | 6.10% | Shares |
| MORGAN STANLEY | $57,477,400 | 2,557,961 | 4.90% | Shares |
| Juniper Investment Company, LLC | $45,386,816 | 2,019,885 | 3.87% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $45,043,789 | 2,004,619 | 3.84% | Shares |
| FMR LLC | $44,119,203 | 1,963,471 | 3.76% | Shares |
| STATE STREET CORP | $41,750,406 | 1,858,051 | 3.56% | Shares |
| Ophir Asset Management Pty Ltd | $40,446,180 | 1,800,008 | 3.45% | Shares |
| PERCEPTIVE ADVISORS LLC | $39,036,906 | 1,737,290 | 3.33% | Shares |
| Conestoga Capital Advisors, LLC | $36,484,539 | 1,623,700 | 3.11% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $28,318,470 | 1,260,279 | 2.41% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $25,043,403 | 1,114,297 | 2.13% | Shares |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $23,011,325 | 1,024,091 | 1.96% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $22,205,281 | 988,219 | 1.89% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $21,300,127 | 947,941 | 1.82% | Shares |
| CITADEL ADVISORS LLC | $18,596,037 | 827,594 | 1.59% | Shares |
| YARGER WEALTH STRATEGIES, LLC | $15,278,432 | 634,223 | 1.30% | Shares |
| ROYCE & ASSOCIATES LP | $14,364,667 | 639,282 | 1.22% | Shares |
| NORTHERN TRUST CORP | $12,370,454 | 550,532 | 1.05% | Shares |
| BANK OF AMERICA CORP /DE/ | $11,716,689 | 521,437 | 1.00% | Shares |
| Qube Research & Technologies Ltd | $10,704,820 | 476,405 | 0.91% | Shares |
| FRED ALGER MANAGEMENT, LLC | $10,406,104 | 463,111 | 0.89% | Shares |
| UBS Group AG | $10,210,390 | 454,401 | 0.87% | Shares |
| TWO SIGMA ADVISERS, LP | $9,974,907 | 218,700 | 0.85% | Shares |
| Invesco Ltd. | $9,956,839 | 443,117 | 0.85% | Shares |
| GOLDMAN SACHS GROUP INC | $9,857,903 | 438,714 | 0.84% | Shares |
| D. E. Shaw & Co., Inc. | $9,846,714 | 438,216 | 0.84% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9,183,579 | 408,704 | 0.78% | Shares |
| Toroso Investments, LLC | $9,018,146 | 197,723 | 0.77% | Shares |
| Soleus Capital Management, L.P. | $8,718,360 | 388,000 | 0.74% | Shares |
| TWO SIGMA INVESTMENTS, LP | $8,702,159 | 387,279 | 0.74% | Shares |
| Balyasny Asset Management L.P. | $8,584,686 | 382,051 | 0.73% | Shares |
| First Eagle Investment Management, LLC | $7,787,496 | 346,573 | 0.66% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $6,978,103 | 310,552 | 0.59% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $6,611,371 | 294,231 | 0.56% | Shares |
| Legal & General Group Plc | $5,826,427 | 259,298 | 0.50% | Shares |
| WASATCH ADVISORS LP | $5,726,929 | 156,388 | 0.49% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $5,705,178 | 253,902 | 0.49% | Shares |
| Bank of New York Mellon Corp | $5,671,109 | 252,386 | 0.48% | Shares |
| Quantinno Capital Management LP | $4,497,191 | 200,142 | 0.38% | Shares |
| AMERIPRISE FINANCIAL INC | $4,348,978 | 193,546 | 0.37% | Shares |
| FIFTH THIRD BANCORP | $4,170,912 | 185,621 | 0.36% | Shares |
| ORBIMED ADVISORS LLC | $3,932,250 | 175,000 | 0.34% | Shares |
| Corient Private Wealth LP | $3,580,552 | 159,348 | 0.31% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3,324,253 | 90,777 | 0.28% | Shares |
| Public Sector Pension Investment Board | $3,298,304 | 146,787 | 0.28% | Shares |
| Parkman Healthcare Partners LLC | $3,121,982 | 138,940 | 0.27% | Shares |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $2,879,149 | 128,133 | 0.25% | Shares |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $2,857,263 | 127,159 | 0.24% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Juniper Targeted Opportunity Fund, L.P., Juniper HF Investors II, LLC, Juniper Targeted Opportunities, L.P., Juniper Targeted Opportunity Investors, LLC, Juniper Multi-Strategy Fund, L.P., Juniper HF Investors, LLC, Juniper Investment Company, LLC, Alexis P. Michas, John A. Bartholdson ×2 filings | Aug. 12, 2025 | 4.00% | Amendment | · | SEC |
| CryoLife, Inc., CL Falcon, Inc. | May 11, 2011 | · | Initial filing | M&A / sale | SEC |
| Michael A. Roth and Brian J. Stark, as joint filers pursuant to Rule 13d-1(k) | July 10, 2007 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Dec. 2, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | March 18, 2005 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 49 insiders · 30 officers · 15 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| James P Mackin | President & CEO | Aug. 19, 2026 S | 877,275 | 0 | 9 | $-9,722,946 |
| Lance A Berry | EVP, COO, CFO & Treasurer | Aug. 14, 2026 S | 210,112 | 0 | 5 | $-803,205 |
| David Ashley Lee | Executive VP, COO & CFO | March 2, 2023 S | 347,217 | 0 | 0 | $0 |
| Andrew M Green | SVP, Regulatory and Quality | Sept. 10, 2026 S | 40,160 | 0 | 6 | $-1,431,215 |
| Jean F Holloway | SVP, General Counsel | Aug. 12, 2026 S | 184,118 | 0 | 13 | $-2,537,794 |
| Marshall S. Stanton | SVP, Clinical & MD Affair | March 3, 2026 S | 60,097 | 0 | 13 | $-3,426,956 |
| John E Davis | Chief Commercial Officer | March 3, 2026 S | 230,794 | 0 | 9 | $-1,745,924 |
| Amy Horton | VP, Chief Accounting Officer | March 3, 2026 S | 139,088 | 0 | 8 | $-870,080 |
| Matthew A Getz | VP, Human Resources | Aug. 16, 2024 S | 34,116 | 0 | 0 | $0 |
| Florian Tyrs | VP, Global Operations | Feb. 27, 2024 S | 21,558 | 0 | 0 | $0 |
| Rochelle L. Maney | VP, Quality | Feb. 26, 2024 S | 44,518 | 0 | 0 | $0 |
| Robert C Thomson | VP Research & Development | Feb. 23, 2024 A | 13,291 | 0 | 0 | $0 |
| Dennis B Maier | SVP, Operations | June 6, 2023 S | 34,724 | 0 | 0 | $0 |
| Franz Peter Barthold | VP, Research & Development | Nov. 8, 2022 A | 32,516 | 0 | 0 | $0 |
| Scott B Capps | VP, Clinical Research | March 12, 2021 F | 153,203 | 0 | 0 | $0 |
| James M Mcdermid | SVP, CHRO | March 14, 2019 F | 30,806 | 0 | 0 | $0 |
| Sherry M Saurini | VP, Quality | March 14, 2019 F | 25,084 | 0 | 0 | $0 |
| William Robert Matthews | Senior VP, Operations, Quality | March 5, 2018 F | 39,883 | 0 | 0 | $0 |
| David C Gale | VP, Research & Development | Nov. 16, 2017 M | 77,135 | 0 | 0 | $0 |
| Steven G Anderson | Former Executive Chairman | April 9, 2015 F | 1,271,846 | 0 | 0 | $0 |
| Bruce G. Anderson | VP, US Sales &Global Marketing | March 7, 2015 F | 42,106 | 0 | 0 | $0 |
| FRONK DAVID | VP, Regulatory Affairs | March 7, 2015 F | 110,559 | 0 | 0 | $0 |
| David P. Lang | VP, Int'l Sales & Marketing | Feb. 26, 2015 A | 73,441 | 0 | 0 | $0 |
| Jeffrey W Burris | Vice President & Gen. Counsel | Aug. 15, 2014 M | 95,221 | 0 | 0 | $0 |
| Gerald B Seery | Sr. VP, Sales and Marketing | Nov. 30, 2012 S | 71,999 | 0 | 0 | $0 |
| Albert E Heacox | Sr. VP Research and Devl | Dec. 31, 2011 F | 110,144 | 0 | 0 | $0 |
| Philip A Theodore | VP, General Counsel | Sept. 4, 2007 A | 23,100 | 0 | 0 | $0 |
| Sidney B Ashmore | Vice President of Marketing | Jan. 18, 2006 M | 42,728 | 0 | 0 | $0 |
| Kirby S Black | Sr. Vice President, R&D | Sept. 21, 2004 M | 55,131 | 0 | 0 | $0 |
| Vander James C Wyk | VP - Product Integrity | Sept. 14, 2004 M | 36,165 | 0 | 0 | $0 |
| Anthony B. Semedo | Director | June 2, 2026 J | 6,325 | 0 | 0 | $0 |
| Elizabeth A Hoff | Director | May 18, 2026 A | 34,765 | 0 | 1 | $-189,420 |
| Marna P Borgstrom | Director | May 18, 2026 A | 56,664 | 0 | 0 | $0 |
| Jon W Salveson | Director | May 18, 2026 A | 137,416 | 0 | 0 | $0 |
| Jeffrey H Burbank | Director | May 18, 2026 A | 61,372 | 0 | 0 | $0 |
| Daniel J Bevevino | Director | May 18, 2026 A | 157,637 | 0 | 0 | $0 |
| Bullock James | Director | May 18, 2026 A | 76,223 | 0 | 0 | $0 |
| Thomas F Ackerman | Director | May 18, 2026 A | 157,472 | 0 | 0 | $0 |
| Harvey Morgan | Director | Aug. 30, 2021 G | 46,342 | 0 | 0 | $0 |
| Ronald D Mccall | Director | Aug. 25, 2021 S | 121,768 | 0 | 0 | $0 |
| Elkins C Ronald | Director | Sept. 5, 2018 S | 64,843 | 0 | 0 | $0 |
| James Benson | Director | Oct. 2, 2017 S | 54,086 | 0 | 0 | $0 |
| John M Cook | Director | June 9, 2009 M | 85,000 | 0 | 0 | $0 |
| LACY VIRGINIA C | Director | April 24, 2007 S | 255,280 | 0 | 0 | $0 |
| VAN DYNE BRUCE J MD | Director | Aug. 1, 2006 A | 12,800 | 0 | 0 | $0 |
| OSS CAPITAL MANAGEMENT | 10% owner | May 31, 2007 S | 1,918,000 | 0 | 0 | $0 |
| Michael S Simpson | · | March 5, 2021 F | 33,698 | 0 | 0 | $0 |
| Thomas J Bogenschuetz | · | May 5, 2020 A | 23,451 | 0 | 0 | $0 |
| Thomas J Lynch | · | Nov. 2, 2004 A | 5,000 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 36 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.64% | 42,246 NS | July 31, 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 0.59% | 46,432 SH | Oct. 2, 2026 | Daily |
| RZG · Invesco Exchange-Traded Fund Trust | 0.40% | 21,951 SH | Oct. 2, 2026 | Daily |
| EBIT · Harbor ETF Trust | 0.25% | 1,133 NS | July 31, 2026 | N-PORT |
| ESSC · Strategy Shares | 0.17% | 2,304 NS | July 31, 2026 | N-PORT |
| IHI · iShares Trust | 0.16% | 203,954 SH | Sept. 11, 2026 | Daily |
| VIOG · VANGUARD ADMIRAL FUNDS | 0.10% | 50,848 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.07% | 429,440 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.06% | 49,054 SH | Aug. 19, 2026 | Daily |
| VIOO · VANGUARD ADMIRAL FUNDS | 0.05% | 148,966 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.04% | 21,860 NS | July 31, 2026 | N-PORT |
| ISCG · iShares Trust | 0.04% | 14,453 SH | Sept. 11, 2026 | Daily |
| IWM · iShares Trust | 0.04% | 1,164,969 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.03% | 263,046 SH | Aug. 19, 2026 | Daily |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0.03% | 23,979 SH | Oct. 2, 2026 | Daily |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.03% | 30,302 SH | Oct. 2, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.02% | 124,676 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 20,435 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 495,296 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 127,662 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 2,287 SH | Sept. 11, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.01% | 1,400 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.01% | 90,038 NS | July 31, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 3,634 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 4,761 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 9,530 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 13,831 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 61,878 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 10,858 SH | Sept. 11, 2026 | Daily |
| DFAT · Dimensional ETF Trust | 0.00% | 2,692 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1,463,340 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3,652 SH | Aug. 19, 2026 | Daily |
| IJR · iShares Trust | · | 2,603,782 SH | Sept. 10, 2026 | Daily |
| IJT · iShares Trust | · | 403,685 SH | Sept. 9, 2026 | Daily |
| XJR · iShares Trust | · | 5,899 SH | Sept. 2, 2026 | Daily |
| ISCB · iShares Trust | · | 2,111 SH | Sept. 11, 2026 | Daily |
AORT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 14 analysts
BUY
Median target
$42.00
+88.3%
5 35.7%
Strong Buy
8 57.1%
Buy
1 7.1%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
8 analysts · 2026-09-29Mean target $42.15 +88.9%
← Below all targets
Current price $22.31
Low$38.00
Mean$42.15
High$48.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| AORT | $2.25B | 217.2 | 13.6% | 2.2% | 2.2% | 64.4% |
| IRMD | $1.24B | 55.6 | 14.4% | 26.8% | 23.8% | 76.8% |
| IART | · | -1.8 | 1.5% | -31.6% | -49.6% | · |
| ENOV | $1.52B | -1.3 | 6.7% | -52.7% | -58.5% | 59.8% |
| BBNX | $1.35B | -16.8 | 53.9% | -73.0% | -24.9% | 55.4% |
| PRCT | $1.77B | -18.3 | 37.2% | -31.0% | -25.4% | 63.7% |
| CBLL | $822M | -15.0 | 36.1% | -60.0% | -32.6% | 87.9% |
| SIBN | $861M | -44.8 | 20.2% | -9.4% | -10.9% | 79.6% |
| VREX | $498M | -7.0 | 4.1% | -8.3% | -14.0% | 34.4% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 7, 2026